Brand-name drug
Rinvoq price, strengths & recalls
Brand of upadacitinib (generic)
Pharmacies pay $6,884.85 for 30 tablets of Rinvoq 15 mg (24 hr) extended-release tablet this week, and from $6,881.15 to $13,795.29 across its 3 priced strengths and forms. Its official label last changed on July 15, 2026.
Brand- Fair cash price
- $7,928.08
- Strengths
- 3
- Makers
- 1
- Updated
- Nov 11
Rinvoq price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 15 mg (24 hr) extended-release tablet Brand | $229.50 | $6,884.85 / 30 tablets |
| 30 mg (24 hr) extended-release tablet Brand | $229.37 | $6,881.15 / 30 tablets |
| 45 mg (24 hr) extended-release tablet Brand | $459.84 | $13,795.29 / 30 tablets |
The lowest cost per tablet is 30 mg (24 hr) extended-release tablet at $229.37. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Rinvoq vs generic upadacitinib
There is no generic version of Rinvoq on the market yet. Its last listed patent or exclusivity runs to March 9, 2038 - generics often follow, though court cases and settlements can move the date either way.
GenericUpadacitinib pricesSupply status: shortages & recalls
What people paid for Rinvoq
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use RINVOQ/RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ/RINVOQ LQ. RINVOQ® (upadacitinib) extended-release tablets, for oral use RINVOQ® LQ (upadacitinib) oral solutionInitial U.S. Approval: 2019
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS
SERIOUS INFECTIONS
Patients treated with RINVOQ/RINVOQ LQ are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
If a serious infection develops, interrupt RINVOQ/RINVOQ LQ until the infection is controlled.
Reported infections include:
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ/RINVOQ LQ use and during therapy. Treatment for latent infection should be considered prior to RINVOQ/RINVOQ LQ use.
Invasive fungal infections, including cryptococcosis and pneumocystosis.
Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.
The risks and benefits of treatment with RINVOQ/RINVOQ LQ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with RINVOQ/RINVOQ LQ, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1)].
MORTALITY
In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions (5.2)].
MALIGNANCIES
Lymphoma and other malignancies have been observed in patients treated with RINVOQ. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3)].
MAJOR ADVERSE CARDIOVASCULAR EVENTS
In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue RINVOQ/RINVOQ LQ in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)].
THROMBOSIS
Thromboses, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. Many of these adverse events were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid RINVOQ/RINVOQ LQ in patients at risk. Patients with symptoms of thrombosis should discontinue RINVOQ/RINVOQ LQ and be promptly evaluated [see Warnings and Precautions (5.5)].
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS
See full prescribing information for complete boxed warning.
Increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with RINVOQ/RINVOQ LQ if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)
Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK) inhibitor vs. tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients. (5.2)
Malignancies have occurred in patients treated with RINVOQ. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)
Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)
Thrombosis has occurred in patients treated with RINVOQ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)
Recent major changes (as listed on the label)
Indications and Usage (1.4, 1.5) | 10/2025 |
Warnings and Precautions (5.8) | 6/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA211675 · Abbvie
- First approved
- August 16, 2019 (7 years ago)
- Latest approved change
- June 30, 2026
- Approved label
- PDF, Jul 6, 2026
- Generic makers
- None on the market
- Last patent listed
- March 9, 2038
- Exclusivity ends
- April 28, 2032
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Rinvoq questions
How much does rinvoq cost without insurance?
Pharmacies pay about $6,884.85 for 30 tablets of rinvoq 15 mg (24 hr) extended-release tablet ($229.50 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $7,928.08. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Rinvoq?
Yes: upadacitinib. Compare upadacitinib prices.
Is rinvoq in shortage?
No shortage is reported for rinvoq right now. We check the national shortage list every day.
Has rinvoq been recalled?
No recalls are on record for rinvoq.
When did the rinvoq label last change?
The official label was last updated on July 15, 2026 (version 101). See what changed.
Talk about rinvoq
No comments yet. Questions, tips, what worked for you - start the conversation.